Corcept Therapeutics Inc
XMUN:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
XMUN:HTD
|
US |
|
Cogent Communications Holdings Inc
NASDAQ:CCOI
|
US |
|
H
|
Humana Inc
XMUN:HUM
|
US |
|
C
|
Credit Suisse Group AG
XHAM:CSX
|
CH |
|
S
|
Smoore International Holdings Ltd
OTC:SMORF
|
CN |
|
M
|
Mondelez International Inc
DUS:KTF
|
US |
|
P
|
Panasonic Holdings Corp
F:MAT1
|
JP |
|
T
|
Thales SA
OTC:THLEF
|
FR |
|
V
|
Veranda Resort PCL
SET:VRANDA
|
TH |
|
B
|
Birkenstock Holding PLC
XBER:7PV
|
UK |
|
P
|
Preferred Bank
F:1IU
|
US |
|
Emperador Inc
XPHS:EMI
|
PH |
|
F
|
Fabrinet
XBER:FAN
|
KY |
Corcept Therapeutics Inc
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses. Corcept makes money mostly by selling its medicine to specialty pharmacies and other healthcare channels, which then dispense it to patients with a doctor’s prescription. Its customers are not everyday consumers; they are hospitals, endocrinologists, specialists, pharmacies, and the patients they treat. Because these drugs are used for rare and complex conditions, Corcept’s business depends on physician adoption, patient access, and insurance coverage rather than broad retail sales. What makes Corcept’s business model distinctive is its narrow focus on cortisol biology. Instead of being a broad pharmaceutical company, it concentrates on a small set of hormone-related diseases where it can build deep expertise and develop targeted treatments. That gives it a clear role in the healthcare value chain: it turns specialized research into niche prescription medicines for hard-to-treat endocrine disorders.
Corcept Therapeutics is a specialty drug company focused on medicines that block the effects of cortisol, a hormone the body makes naturally. Its main commercial product is Korlym, a prescription drug used to treat certain patients with endogenous Cushing’s syndrome, a serious disorder caused by too much cortisol. The company also develops related cortisol-modulating drugs for other medical uses.
Corcept makes money mostly by selling its medicine to specialty pharmacies and other healthcare channels, which then dispense it to patients with a doctor’s prescription. Its customers are not everyday consumers; they are hospitals, endocrinologists, specialists, pharmacies, and the patients they treat. Because these drugs are used for rare and complex conditions, Corcept’s business depends on physician adoption, patient access, and insurance coverage rather than broad retail sales.
What makes Corcept’s business model distinctive is its narrow focus on cortisol biology. Instead of being a broad pharmaceutical company, it concentrates on a small set of hormone-related diseases where it can build deep expertise and develop targeted treatments. That gives it a clear role in the healthcare value chain: it turns specialized research into niche prescription medicines for hard-to-treat endocrine disorders.
Revenue: First-quarter revenue was $164.9 million, up from $157.2 million a year ago, and management raised full-year 2026 revenue guidance to $950 million to $1.05 billion.
Endocrinology growth: Corcept said demand for its Cushing's syndrome medicines is accelerating, with record new prescriptions, record prescribers, and all-time high patient counts, though first-quarter revenue lagged the underlying momentum because of insurance reauthorization delays and a pharmacy transition.
Oncology launch: Lifyorli was approved 3.5 months early for platinum-resistant ovarian cancer, and management said the launch is off to a strong start with more than 200 physicians already writing prescriptions and NCCN preferred status helping access.
Pipeline breadth: The company highlighted relacorilant in Cushing's syndrome, new oncology studies, the Phase II MONARCH trial in MASH, and a planned Phase III ALS study for dazucorilant.
Long-term outlook: Management reiterated ambitious long-term targets, including at least $2 billion in annual revenue for the current Cushing's business by the end of the decade and more than $1 billion annually in U.S. revenue for Lifyorli by then.
